Silicon Valley Computational Drug Startup Takes on Glaucoma

IEEE Spectrum ------- About a year ago I met two Silicon Valley entrepreneurs named Andrew Radin, whose matching names generated competition over an Internet domain, a connection, and eventually, a company. The startup is called, twoXAR, an abbreviation of “two times Andrew Radin.” The pair presented an ambitious agenda, they were aiming to revolutionize drug discovery with an algorithm that could mine data sets to identify the most promising candidates for an effective drug, allowing pharmaceutical companies to fast track only the most likely prospects into testing. Explained one of the Andrews, Andrew A. Radin, in a blog post: Our platform does not use molecular modeling techniques. Instead, it uses twoXAR-developed AI-based algorithms trained on large and diverse sets of real world biomedical data about diseases and drugs to predict which molecules might be most effective. These biomedical data include gene expression measurements, protein interaction networks, and clinical records. To learn more click on the picture below to read the article.